Korean J Dermatol.  2015 Jun;53(5):388-391.

Imatinib-induced Psoriasiform Drug Eruption in a Patient with a Gastrointestinal Stromal Tumor

• Lee YJ
• Lee WJ
• Chang S
• Lee MW
• Choi JH
• Moon KC

Abstract

Imatinib mesylate (Gleevec(R)) is a small-molecule inhibitor that selectively inhibits the tyrosine kinase family, including mutated KIT oncoproteins in gastrointestinal stromal tumors (GIST). However, cutaneous reactions to imatinib are common and occur in 7.0% to 88.9% of patients. Nonspecific skin rashes, facial edema, and pruritus are the most common adverse reactions. However, development of psoriasiform drug eruption owing to the drug has rarely been reported. Herein we report on a 66-year-old male patient with GIST who had taken imatinib (400 mg/day) for 2 months. He developed erythematous scaly macules and papules on the trunk and extremities. Histopathological findings were compatible with a psoriasiform drug eruption.

Keyword

Gastrointestinal stromal tumor; Gleevec; Imatinib mesylate; Psoriasis

MeSH Terms

Aged
Drug Eruptions*
Edema
Exanthema
Extremities
Gastrointestinal Stromal Tumors*
Humans
Male
Mesylates
Oncogene Proteins
Protein-Tyrosine Kinases
Pruritus
Psoriasis
Imatinib Mesylate
Mesylates
Oncogene Proteins
Protein-Tyrosine Kinases